Assyro AI

Orange Book product · Brand (NDA)

SLYND

DROSPIRENONE

Brand (NDA)NDA 211367RX EXELTIS USA INC

At a glance

May 23, 2019

Approved

Brand (NDA)

Application

Not listed

TE code

15

Listed patents

Key dates

  1. Approval

    FDA approval date of this drug product.

    May 23, 2019

    7 yr 2 mo ago

  2. Today

  3. Patent 10179140 expires

    Listed method-of-use patent (U-2553) expiration.

    Jun 28, 2031

    in 5 yr 1 mo

  4. Patent 10603281 expires

    Listed method-of-use patent (U-2553) expiration.

    Jun 28, 2031

    in 5 yr 1 mo

  5. Patent 10849857 expires

    Listed drug product patent expiration.

    Jun 28, 2031

    in 5 yr 1 mo

  6. Patent 10987364 expires

    Listed drug product patent expiration.

    Jun 28, 2031

    in 5 yr 1 mo

  7. Patent 11123299 expires

    Listed drug product patent expiration.

    Jun 28, 2031

    in 5 yr 1 mo

  8. Patent 11291632 expires

    Listed drug product patent expiration.

    Jun 28, 2031

    in 5 yr 1 mo

  9. Patent 11291633 expires

    Listed drug product patent expiration.

    Jun 28, 2031

    in 5 yr 1 mo

  10. Patent 11351122 expires

    Listed drug product patent expiration.

    Jun 28, 2031

    in 5 yr 1 mo

  11. Patent 11413249 expires

    Listed method-of-use patent (U-2553) expiration.

    Jun 28, 2031

    in 5 yr 1 mo

  12. Patent 11478487 expires

    Listed drug product patent expiration.

    Jun 28, 2031

    in 5 yr 1 mo

  13. Patent 11504334 expires

    Listed drug product patent expiration.

    Jun 28, 2031

    in 5 yr 1 mo

  14. Patent 11951213 expires

    Listed method-of-use patent (U-2553) expiration.

    Jun 28, 2031

    in 5 yr 1 mo

  15. Patent 12090231 expires

    Listed method-of-use patent (U-2553) expiration.

    Jun 28, 2031

    in 5 yr 1 mo

  16. Patent 12280151 expires

    Listed drug product patent expiration.

    Jun 28, 2031

    in 5 yr 1 mo

  17. Patent 9603860 expires

    Listed method-of-use patent (U-2553) expiration.

    Jun 28, 2031

    in 5 yr 1 mo

Pharmaceutical detail

Active ingredient

DROSPIRENONE

Strength

4MG

Dosage form

TABLET

Route

ORAL

TE code

Not listed

Application

NDA 211367

Product number

001

Marketing status

RX

Reference listed drug (RLD)

Yes

Reference standard (RS)

Yes

Active-ingredient family

View full family

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Listed patents (15)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
10179140Jun 28, 2031in 5 yr 1 mo
U-2553
10603281Jun 28, 2031in 5 yr 1 mo
U-2553
10849857Jun 28, 2031in 5 yr 1 mo
ProductU-2553
10987364Jun 28, 2031in 5 yr 1 mo
Product
11123299Jun 28, 2031in 5 yr 1 mo
Product
11291632Jun 28, 2031in 5 yr 1 mo
Product
11291633Jun 28, 2031in 5 yr 1 mo
Product
11351122Jun 28, 2031in 5 yr 1 mo
Product
11413249Jun 28, 2031in 5 yr 1 mo
U-2553
11478487Jun 28, 2031in 5 yr 1 mo
Product
11504334Jun 28, 2031in 5 yr 1 mo
Product
11951213Jun 28, 2031in 5 yr 1 mo
U-2553
12090231Jun 28, 2031in 5 yr 1 mo
U-2553
12280151Jun 28, 2031in 5 yr 1 mo
Product
9603860Jun 28, 2031in 5 yr 1 mo
U-2553
Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.